Brown Advisory’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-31,822
Closed -$4.55M 1204
2021
Q4
$4.55M Sell
31,822
-1,000
-3% -$172K 0.01% 490
2021
Q3
$6.8M Buy
32,822
+60
+0.2% +$13.2K 0.01% 420
2021
Q2
$6.96M Sell
32,762
-293
-0.9% -$53.7K 0.01% 421
2021
Q1
$5.99M Buy
33,055
+29,585
+853% +$5.9M 0.01% 437
2020
Q4
$387K Hold
3,470
﹤0.01% 832
2020
Q3
$376K Sell
3,470
-37,000
-91% -$4.51M ﹤0.01% 783
2020
Q2
$3.37M Sell
40,470
-6,625
-14% -$253K 0.01% 434
2020
Q1
$639K Buy
47,095
+13,295
+39% +$112K ﹤0.01% 638
2019
Q4
$134K Sell
33,800
-2,000
-6% -$8.67K ﹤0.01% 1004
2019
Q3
$179K Buy
35,800
+10,650
+42% +$58.3K ﹤0.01% 956
2019
Q2
$147K Buy
25,150
+11,500
+84% +$90.5K ﹤0.01% 991
2019
Q1
$150K Buy
13,650
+4,373
+47% +$138K ﹤0.01% 1268
2018
Q4
$341K Hold
9,277
﹤0.01% 1039
2018
Q3
$349K Hold
9,277
﹤0.01% 1109
2018
Q2
$249K Hold
9,277
﹤0.01% 1163
2018
Q1
$390K Sell
9,277
-3,318
-26% -$133K ﹤0.01% 897
2017
Q4
$312K Buy
12,595
+4,460
+55% +$109K ﹤0.01% 1032
2017
Q3
$185K Buy
8,135
+3,480
+75% +$77.9K ﹤0.01% 1132
2017
Q2
$108K Sell
4,655
-34
-0.7% -$667 ﹤0.01% 1186
2017
Q1
$120K Sell
4,689
-250
-5% -$6.88K ﹤0.01% 1131
2016
Q4
$124K Sell
4,939
-2,980
-38% -$86.9K ﹤0.01% 1095
2016
Q3
$329K Buy
7,919
+3,230
+69% +$417K ﹤0.01% 853
2016
Q2
$682K Hold
4,689
﹤0.01% 667
2016
Q1
$484K Buy
4,689
+350
+8% +$37.5K ﹤0.01% 727
2015
Q4
$728K Buy
4,339
+20
+0.5% +$3.08K ﹤0.01% 615
2015
Q3
$610K Buy
4,319
+75
+2% +$16.8K ﹤0.01% 648
2015
Q2
$945K Hold
4,244
﹤0.01% 536
2015
Q1
$702K Hold
4,244
﹤0.01% 621
2014
Q4
$503K Buy
4,244
+694
+20% +$72.5K ﹤0.01% 684
2014
Q3
$296K Hold
3,550
﹤0.01% 801
2014
Q2
$328K Hold
3,550
﹤0.01% 778
2014
Q1
$322K Buy
3,550
+150
+4% +$16.8K ﹤0.01% 769
2013
Q4
$348K Hold
3,400
﹤0.01% 721
2013
Q3
$215K Hold
3,400
﹤0.01% 781
2013
Q2
$140K Buy
+3,400
New +$147K ﹤0.01% 775

Other funds holding NVAX

Brown Advisory's NVAX Position: Q1 2022 in Review

Brown Advisory sold out of Novavax (NVAX) in Q1 2022, closing a stake of 31,822 shares — an estimated $4.55M sold.

Brown Advisory first reported a position in NVAX in Q2 2013 and held it in 35 quarters. The position peaked at $6.96M in Q2 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

  • Brown Advisory reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
  • Brown Advisory sold 31,822 Novavax shares in Q1 2022, an estimated $4.55M.
  • Brown Advisory first reported a position in Novavax in Q2 2013 and held it in 35 quarters.
  • Brown Advisory's Novavax position peaked at $6.96M in Q2 2021.
  • 381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on Brown Advisory's 13F filing for Q1 2022, filed 9 May 2022.